Future of automated insulin delivery systems

Jessica R. Castle, J. Hans DeVries, Boris Kovatchev

Research output: Contribution to journalArticlepeer-review

30 Scopus citations


Advances in continuous glucose monitoring (CGM) have brought on a paradigm shift in the management of type 1 diabetes. These advances have enabled the automation of insulin delivery, where an algorithm determines the insulin delivery rate in response to the CGM values. There are multiple automated insulin delivery (AID) systems in development. A system that automates basal insulin delivery has already received Food and Drug Administration approval, and more systems are likely to follow. As the field of AID matures, future systems may incorporate additional hormones and/or multiple inputs, such as activity level. All AID systems are impacted by CGM accuracy and future CGM devices must be shown to be sufficiently accurate to be safely incorporated into AID. In this article, we summarize recent achievements in AID development, with a special emphasis on CGM sensor performance, and discuss the future of AID systems from the point of view of their input-output characteristics, form factor, and adaptability.

Original languageEnglish (US)
Pages (from-to)S67-S72
JournalDiabetes Technology and Therapeutics
StatePublished - Jun 2017


  • Artificial pancreas
  • Continuous glucose monitoring
  • Type 1 diabetes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Medical Laboratory Technology


Dive into the research topics of 'Future of automated insulin delivery systems'. Together they form a unique fingerprint.

Cite this